

FOR IMMEDIATE RELEASE

Contact: Media (602) 346-5302
www.covancechandler.com

COVANCE FILES APPLICATION FOR RE-ZONING OF PRICE CORRIDOR PROPERTY

Princeton, New Jersey, July 14, 2006 - Covance has filed an application to re-zone the Price Corridor property in Chandler, Arizona. Covance bought the 38-acre property for \$8 million for potential business expansion opportunities. Current plans are to build a state-of-the-art medical research facility that will help pharmaceutical and biotech companies test the safety of new drug candidates.

“We are pleased with the reception we have received from not only Chandler’s scientific and medical community, but by its local citizens, as well,” said Wendel Barr, Senior Vice President at Covance. “We are looking forward to the new facility’s potential to diversify Chandler’s economy. It will help to create hundreds of stable, well-paying jobs, many going to science and health professionals. We hope this facility will attract other bioscience companies that can help to establish Chandler as a growing center of medical research. We very much look forward to being a good neighbor to the people of Chandler.”

For over 50 years, Covance has made significant contributions to the development of life-saving and life-enhancing new medicines for HIV/AIDS, breast cancer, heart disease, leukemia, diabetes, Alzheimer’s, multiple sclerosis, cystic fibrosis, deadly infections, and many other disabling diseases. More information about the Covance Chandler property can be found on www.covancechandler.com

Covance (NYSE: CVD), is one of the world's largest and most comprehensive drug development services companies with a market capitalization of \$3.8 billion, global operations in more than 20 countries, and more than 7,800 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through www.covance.com